Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Clonal approaches to understanding the impact of mutations on hematologic disease development.

Nangalia J, Mitchell E, Green AR.

Blood. 2019 Feb 6. pii: blood-2018-11-835405. doi: 10.1182/blood-2018-11-835405. [Epub ahead of print]

PMID:
30728143
2.

No place for 'trial by media' in bullying allegations.

Collord G, Nangalia J, Moore L.

Nature. 2018 Dec;564(7735):190. doi: 10.1038/d41586-018-07723-0. No abstract available.

PMID:
30542173
3.

A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ; BSH Committee.

Br J Haematol. 2019 Jan;184(2):176-191. doi: 10.1111/bjh.15648. Epub 2018 Nov 27. No abstract available.

PMID:
30478826
4.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, Knapper S, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Harrison CN; British Society for Haematology Guideline.

Br J Haematol. 2019 Jan;184(2):161-175. doi: 10.1111/bjh.15647. Epub 2018 Nov 13. No abstract available.

PMID:
30426472
5.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

PMID:
30304655
6.

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, McMullin MF, Forsyth C, Kiladjian JJ, Green AR, Harrison CN; United Kingdom Medical Research Council Primary Thrombocythemia-1 Study; United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup; French Intergroup of Myeloproliferative Neoplasms; and the Australasian Leukaemia and Lymphoma Group.

J Clin Oncol. 2018 Aug 28:JCO2018788414. doi: 10.1200/JCO.2018.78.8414. [Epub ahead of print]

7.

Myeloproliferative neoplasms: from origins to outcomes.

Nangalia J, Green AR.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):470-479. doi: 10.1182/asheducation-2017.1.470. Review.

8.

Myeloproliferative neoplasms: from origins to outcomes.

Nangalia J, Green AR.

Blood. 2017 Dec 7;130(23):2475-2483. doi: 10.1182/blood-2017-06-782037. Review.

9.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN.

Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.

PMID:
28336242
10.

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

Grinfeld J, Nangalia J, Green AR.

Haematologica. 2017 Jan;102(1):7-17. doi: 10.3324/haematol.2014.113845. Epub 2016 Dec 1. Review.

11.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2016 May;26(5):717.2. doi: 10.1101/gr.206557.116. No abstract available.

12.

Pathogenesis of Myeloproliferative Disorders.

Nangalia J, Grinfeld J, Green AR.

Annu Rev Pathol. 2016 May 23;11:101-26. doi: 10.1146/annurev-pathol-012615-044454. Review.

PMID:
27193452
13.

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A.

Cell Rep. 2015 Dec 22;13(11):2345-2352. doi: 10.1016/j.celrep.2015.11.037. Epub 2015 Dec 10.

14.

Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.

Malherbe JA, Fuller KA, Arshad A, Nangalia J, Romeo G, Hall SL, Meehan KS, Guo B, Howman R, Erber WN.

J Clin Pathol. 2016 Feb;69(2):155-63. doi: 10.1136/jclinpath-2015-203177. Epub 2015 Aug 19.

PMID:
26290261
15.

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, Massie CE, Baxter J, Sewell D, Silber Y, Campbell PJ, Green AR.

Haematologica. 2015 Nov;100(11):e438-42. doi: 10.3324/haematol.2015.129510. Epub 2015 Aug 6. No abstract available.

16.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova SG, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2015 Jun;25(6):814-24. doi: 10.1101/gr.190470.115. Epub 2015 May 11. Erratum in: Genome Res. 2016 May;26(5):717.2.

17.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

18.

The evolving genomic landscape of myeloproliferative neoplasms.

Nangalia J, Green TR.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):287-96. doi: 10.1182/asheducation-2014.1.287. Epub 2014 Nov 18. Review.

PMID:
25696868
19.

Effect of mutation order on myeloproliferative neoplasms.

Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR.

N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098.

20.

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A, Dent CL, White HE, Drexler HG, Nangalia J, Mattocks C, Cross NC.

Leuk Res. 2015 Jan;39(1):82-7. doi: 10.1016/j.leukres.2014.11.019. Epub 2014 Nov 29.

PMID:
25499808
21.

Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

Godfrey AL, Nangalia J, Baxter EJ, Massie CE, Kent DG, Papaemmanuil E, Campbell PJ, Green AR.

Blood. 2014 Nov 20;124(22):3332-4. doi: 10.1182/blood-2014-09-603043. No abstract available.

22.

JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15190-5. doi: 10.1073/pnas.1401873111. Epub 2014 Oct 6.

23.

Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A, Bolli N, Behjati S, Tarpey PS, Nangalia J, Massie CE, Butler AP, Teague JW, Vassiliou GS, Green AR, Du MQ, Unnikrishnan A, Pimanda JE, Teh BT, Munshi N, Greaves M, Vyas P, El-Naggar AK, Santarius T, Collins VP, Grundy R, Taylor JA, Hayes DN, Malkin D; ICGC Breast Cancer Group; ICGC Chronic Myeloid Disorders Group; ICGC Prostate Cancer Group, Foster CS, Warren AY, Whitaker HC, Brewer D, Eeles R, Cooper C, Neal D, Visakorpi T, Isaacs WB, Bova GS, Flanagan AM, Futreal PA, Lynch AG, Chinnery PF, McDermott U, Stratton MR, Campbell PJ.

Elife. 2014 Oct 1;3. doi: 10.7554/eLife.02935.

24.

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E, Scott M, Drexler HG, Green AR.

Leukemia. 2015 Feb;29(2):494-7. doi: 10.1038/leu.2014.285. Epub 2014 Sep 24. No abstract available.

25.

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Li J, Kent DG, Godfrey AL, Manning H, Nangalia J, Aziz A, Chen E, Saeb-Parsy K, Fink J, Sneade R, Hamilton TL, Pask DC, Silber Y, Zhao X, Ghevaert C, Liu P, Green AR.

Blood. 2014 May 15;123(20):3139-51. doi: 10.1182/blood-2013-06-510222. Epub 2014 Apr 1.

26.

CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.

Guglielmelli P, Nangalia J, Green AR, Vannucchi AM.

Am J Hematol. 2014 May;89(5):453-6. doi: 10.1002/ajh.23678. Epub 2014 Mar 11. No abstract available.

27.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

28.

Inactivating CUX1 mutations promote tumorigenesis.

Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, Tiffen JC, Kober C; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, Green AR, Massie CE, Nangalia J, Lempidaki S, Döhner H, Döhner K, Bray SJ, McDermott U, Papaemmanuil E, Campbell PJ, Adams DJ.

Nat Genet. 2014 Jan;46(1):33-8. doi: 10.1038/ng.2846. Epub 2013 Dec 8.

29.

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.

Wyspiańska BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto FJ, Robson S, Rioja I, Li J, Wiese M, Cannizzaro E, Dawson MA, Huntly B, Prinjha RK, Green AR, Gottgens B, Kouzarides T.

Leukemia. 2014 Jan;28(1):88-97. doi: 10.1038/leu.2013.234. Epub 2013 Aug 9.

PMID:
23929215
30.

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

Aziz A, Baxter EJ, Edwards C, Cheong CY, Ito M, Bench A, Kelley R, Silber Y, Beer PA, Chng K, Renfree MB, McEwen K, Gray D, Nangalia J, Mufti GJ, Hellstrom-Lindberg E, Kiladjian JJ, McMullin MF, Campbell PJ, Ferguson-Smith AC, Green AR.

J Clin Invest. 2013 May;123(5):2169-82. doi: 10.1172/JCI66113. Epub 2013 Apr 1.

31.

Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.

Nangalia J, Smith H, Wimperis JZ.

Leuk Lymphoma. 2008 Aug;49(8):1530-6. doi: 10.1080/10428190802210718.

PMID:
18766966
32.

Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

Li W, Adams TE, Nangalia J, Esmon CT, Huntington JA.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4661-6. doi: 10.1073/pnas.0711055105. Epub 2008 Mar 24.

Supplemental Content

Loading ...
Support Center